Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03150004 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03150004 is a Phase 2 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 53 participants.
The verdict
NCT03150004, a Phase 2 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodic intervals to determine the primary and secondary objectives.
Interventions
- DRUG Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
- DRUG Cladribine and Cytarabine (CLLDAC) Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03150004
The ClinicalTrials.gov registry entry for NCT03150004 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen is the first listed.
NCT03150004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03150004 about?
NCT03150004 is a clinical study titled "Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)". This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen and followed at periodic intervals to determine the primary and secondary...
What is the current status of trial NCT03150004?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-06-14. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT03150004?
The interventions under investigation include: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen (DRUG), Cladribine and Cytarabine (CLLDAC) Regimen (DRUG).
Who is sponsoring clinical trial NCT03150004?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.